[Albuquerque, N.M. – 2/5/2026] — Lovelace Biomedical, a not-for-profit preclinical contract research organization (CRO) that helps pharma, biotech, and federal partners generate the early-stage data required to advance therapies toward clinical testing, has appointed Andrew Alexander, DVM, PhD, MBA, DABT, Senior Director of Preclinical Toxicology. In this role, he will focus on operations and scientific rigor across Lovelace’s preclinical research programs.
Dr. Alexander brings more than 30 years of experience in academic research and CROs, with a career centered on building efficient, scalable preclinical operations that deliver high-quality science on predictable timelines. His background spans exploratory, non-GLP, and GLP studies across a wide range of therapeutic modalities, species, and delivery routes.
As Senior Director, Alexander will work closely with study directors, operations, and leadership teams to optimize study design workflows, streamline proposal, quoting, and reporting processes, and support the expansion of new service lines and preclinical research models.
“CROs play a critical role in helping sponsors meet regulatory and development milestones, and execution matters,” said Dr. Alexander. “My focus at Lovelace is on streamlining operational efficiencies, strengthening transparency and communication, and making sure we deliver high-quality science on the timelines our sponsors depend on.”
Prior to joining Lovelace, he held senior leadership roles at Covance (now Labcorp) and Inotiv, overseeing preclinical toxicology, pharmacology, surgical and medical device safety programs. His experience includes study direction, leadership of large multidisciplinary teams, site leadership, full P&L responsibility, capital expansion projects, regulatory inspections, and direct collaboration with sponsors, regulators, and internal scientific staff. He has worked with organizations ranging from early-stage startups to Fortune 500 life science companies. Dr. Alexander holds a Doctor of Veterinary Medicine, a PhD in Biomedical Science, and an MBA, all from the University of Wisconsin, and is a Diplomate of the American Board of Toxicology (DABT).
ABOUT LOVELACE BIOMEDICAL
Lovelace Biomedical is a not-for-profit preclinical CRO that helps pharma, biotech, and federal partners generate the critical safety, PK/TK, pharmacology, and efficacy data required to advance therapies toward clinical testing. With a science-first ethos, deep multidisciplinary expertise, and a secure, centralized high-containment research campus, we deliver rigorous, customized studies for programs ranging from gene therapy to infectious disease and medical countermeasures.